Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Cruz-Teran, Carlos
    • Affiliation: Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
  • Tiruthani, Karthik
    • Affiliation: Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
  • McSweeney, Morgan
    • Other Affiliation: Inhalon Biopharma
  • Ma, Alice
    • Affiliation: School of Medicine, Joint Department of Biomedical Engineering, North Carolina State University
  • Pickles, Raymond
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
  • Lai, Samuel K.
    • Affiliation: Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics
Abstract
  • To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, numerous historical efforts to advance antiviral mAbs for the treatment of other respiratory infections have been met with categorical failures in the clinic. By investigating the mechanism by which SARS-CoV-2 and similar viruses spread within the lung, along with available biodistribution data for systemically injected mAb, we highlight the challenges faced by current antiviral mAbs for COVID-19. We summarize some of the leading mAbs currently in development, and present the evidence supporting inhaled delivery of antiviral mAb as early intervention against COVID-19 that could prevent important pulmonary morbidities associated with the infection.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Advanced Drug Delivery Reviews
Language
  • English
Version
  • Postprint

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 1-s2.0-S0169409X20302751-main.pdf 2021-01-04 Public Download